-

$undefined

N/A

(N/A)

Outlook Therapeutics NASDAQ:OTLK Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010/LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating a range of retinal diseases in the United States, United Kingdom, Europe, Japan, China and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway, initially for wet AMD.

Location: 485 Route 1 South, Building F, Suite 320, New Jersey, 08830, United States | Website: outlooktherapeutics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

74.31M

Cash

5.703M

Avg Qtr Burn

-16.68M

Short % of Float

19.63%

Insider Ownership

36.42%

Institutional Own.

16.08%

Qtr Updated

12/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease , Wet age-related macular degeneration	PDUFA Approval decision	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Wet age-related macular degeneration , Eye disease	BLA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Eye disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Details Diabetes, Eye disease , BK virus, Adenovirus, Epstein-Barr virus, Human herpesvirus 6, Cytomegalovirus, Diabetic macular edema	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.